Adolescents living with HIV in low- and middle-income African countries experienced better viral suppression and a lower rate of rebound when treated with eight-weekly long-acting injections rather than standard daily pills, a major new clinical trial published in The Lancet has revealed. Conducted across five clinics in Kenya, South Africa, Uganda, and Zimbabwe, the LATA trial evaluated 476 participants aged 12 to 19 who had been stable on oral therapy for over a year, finding that only two adolescents (1 per cent) in the injectable arm suffered viral rebound at 96 weeks compared to 15 adolescents (6 per cent) in the daily tablet group. Commenting on the outcomes, Professor Sarah Pett noted that while adult trials previously showed injectables to be merely non-inferior to pills, the benefits for adolescents are profoundly stronger, helping them escape the daily stigma of pill-taking, a sentiment echoed by 94 per cent of participants who found the bi-monthly regimen much easier to manage. Nevertheless, bringing these therapies to resource-limited settings faces formidable obstacles, including higher drug costs under patent protection, the cold-chain requirements of rilpivirine, and the necessity of trained medical staff for administration every two months, leaving African youth behind while high-income countries already offer these treatments. Researchers, including corresponding author Dr. Deborah Ford and Harare site principal investigator Dr. Mutsa Bwakura-Dangarembizi, cautioned that failing to address these supply and equity gaps risks widening global health divides, even as the trial successfully concluded with support from the European Union, Johnson & Johnson Innovative Medicines, ViiV Healthcare, and academic collaborators across Africa and Europe.
